Table 4.
Antimicrobial susceptibility patterns of Gram-negative isolates from an external eye infection at JUMC ophthalmic clinic.
| Bacterial isolate | Antimicrobial agents tested | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total | Pattern | AMC no. (%) | AMP no. (%) | CIP no. (%) | CRO no. (%) | C no. (%) | CAZ no. (%) | TE no. (%) | SXT no. (%) | CN no. (%) | TOB no. (%) | AK no. (%) | |
| P. aeruginosa | 10 | S | 8 (80.0) | 5 (50.0) | 9 (90.0) | 8 (80.0) | 5 (50.0) | 1 (10.0) | 2 (20.0) | 3 (30.0) | 8 (80.0) | 3 (30.0) | 8 (80.0) |
| R | 2 (20.0) | 5 (50.0) | 1 (10.0) | 2 (20.0) | 5 (50.0) | 9 (90.0) | 8 (80.0) | 7 (70.0) | 2 (20.0) | 7 (70.0) | 2 (20.0) | ||
|
| |||||||||||||
| K. pneumoniae | 9 | S | 8 (88.9) | 6 (66.7) | 9 (100) | 9 (100) | 8 (88.9) | 6 (66.7) | 4 (44.4) | 4 (44.4) | 8 (88.9) | 4 (44.4) | 8 (88.9) |
| R | 1 (11.1) | 3 (33.3) | 0 (0.0) | 0 (0.0) | 1 (11.1) | 3 (33.3) | 5 (55.6) | 5 (55.6) | 1 (11.1) | 5 (55.6) | 1 (11.1) | ||
|
| |||||||||||||
| P. mirabilis | 5 | S | 5 (100) | 4 (80.0) | 5 (100) | 4 (80.0) | 4 (80.0) | 4 (80.0) | 3 (60.0) | 3 (60.0) | 5 (100) | 2 (40.0) | 5 (100) |
| R | 0 (0.0) | 1 (20.0) | 0 (0.0) | 1 (20.0) | 1 (20.0) | 1 (20.0) | 2 (40.0) | 2 (40.0) | 0 (0.0) | 3 (60.0) | 0 (0.0) | ||
|
| |||||||||||||
| P. vulgaris | 4 | S | 4 (100) | 3 (75.0) | 4 (100) | 4 (100) | 4 (100) | 3 (75.0) | 3 (75.0) | 3 (75.0) | 3 (75.5) | 1 (25.0) | 3 (75.0) |
| R | 0 (0.0) | 1 (25.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (25.0) | 1 (25.0) | 1 (25.0) | 1 (25.0) | 3 (75.0) | 1 (25.0) | ||
|
| |||||||||||||
| S. marcescens | 3 | S | 3 (100) | 1 (66.7) | 3 (100) | 3 (100) | 3 (100) | 3 (100) | 2 (66.7) | 0 (0.0) | 3 (100) | 1 (33.3) | 2 (66.7) |
| R | 0 (0.0) | 1 (33.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (33.3) | 3 (100) | 0 (0.0) | 2 (66.7) | 1 (33.3) | ||
|
| |||||||||||||
| Citrobacter spp. | 5 | S | 4 (80.0) | 4 (80.0) | 5 (100) | 5 (100) | 4 (80.0) | 4 (80.0) | 3 (60.0) | 5 (100) | 4 (80.0) | 3 (60.0) | 4 (80.0) |
| R | 1 (20.0) | 1 (20.0) | 0 (0.0) | 0 (0.0) | 1 (20.0) | 1 (20.0) | 2 (40.0) | 0 (0.0) | 1 (20.0) | 2 (40.0) | 1 (20.0) | ||
|
| |||||||||||||
| Enterobacter spp. | 3 | S | 3 (100) | 2 (66.7) | 3 (100) | 3 (100) | 3 (100) | 3 (100) | 1 (33.3) | 3 (100) | 2 (66.7) | 1 (33.3) | 2 (66.7) |
| R | 0 (0.0) | 1 (33.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (66.7) | 0 (0.0) | 1 (33.3) | 2 (66.7) | 1 (33.3) | ||
|
| |||||||||||||
| E. coli | 5 | S | 4 (80) | 3 (60.0) | 5 (100) | 5 (100) | 3 (60.0) | 4 (80.0) | 1 (20.0) | 4 (80.0) | 5 (100) | 2 (40.0) | 4 (80.0) |
| R | 1 (20.0) | 2 (40.0) | 0 (0.0) | 0 (0.0) | 2 (40.0) | 1 (20.0) | 4 (80.0) | 2 (40.0) | 0 (0.0) | 3 (60.0) | 1 (20.0) | ||
|
| |||||||||||||
| H. influenzae | 5 | S | 4 (80.0) | 3 (60.0) | 5 (100) | 5 (100) | 4 (80.0) | 4 (80.0) | 3 (60.0) | 3 (60.0) | 4 (80.0) | NT | NT |
| R | 1 (20.0) | 2 (40.0) | 0 (0.0) | 0 (0.0) | 1 (20.0) | 1 (20.0) | 2 (40.0) | 2 (40.0) | 1 (20.0) | NT | NT | ||
|
| |||||||||||||
| N. meningitidis | 2 | S | NT | NT | 2 (100) | 2 (100) | 1 (50.0) | NT | NT | 1 (50.0) | NT | NT | NT |
| R | NT | NT | 0 (0.0) | 0 (0.0) | 1 (50.0) | NT | NT | 1 (50.0) | NT | NT | NT | ||
S: susceptible; R: resistance; AMC: amoxicillin-clavulanic acid; AMP: ampicillin; CIP: ciprofloxacin; AK: amikacin; C: chloramphenicol; TE : tetracycline; SXT: trimethoprim-sulphamethoxazole; CN: gentamicin; CRO: ceftriaxone; CAZ: ceftazidime; TOB: tobramycin; no.: number; NT: not tested. A few intermediate susceptible isolates were included in the susceptible category.